摘要
背景与目的:对于复发转移性乳腺癌,卡培他滨和紫杉醇类药物均有确切肯定的疗效,由于紫杉醇类药物能增强肿瘤组织的TP活性,因而与卡培他滨有协同作用。本研究观察及评价多西紫杉醇联合卡培他滨治疗复发转移性乳腺癌的疗效和不良反应。方法:22例晚期乳腺癌患者均给予多西紫杉醇75 mg/m2,第1天;卡培他滨口服每日2次,餐后服用,1 000 mg/m2/次,连续服用14天,治疗周期为21天,至少治疗2个周期。结果:本组完全缓解(CR)3例,部分缓解(PR)12例,稳定(SD)6例,疾病进展(PD)1例,总有效率68.2%,中位TTP 6.5个月。不同转移部位或器官的有效率分别为:胸壁85.7%(6/7);淋巴结80.0%(8/10);肺脏75.0%(6/8);骨骼40.0%(2/5);肝脏30.0%(3/10)。Ⅰ/Ⅱ级不良反应为皮肤色素沉着16例,手足综合征14例,恶心呕吐12例,腹泻10例,白细胞下降16例。Ⅲ/Ⅳ级不良反应白细胞下降3例,恶心呕吐1例,贫血1例。结论:多西紫杉醇联合卡培他滨治疗晚期乳腺癌疗效肯定,患者耐受性良好。
Background and Purpose： Capecitabine and doeetaxel have been proved to be effective antineoplastic drugs for the treatment of metastatic breast cancer. This study was designed to observe the response rate and toxicity of the combination of docetaxel plus capecitabine for the treatment of metastatic breast cancer. Methods： Twenty-two breast cancer patients who had recurrent and metastatic measurable foci were enrolled into the trial from Dec. 2002 to Dec, 2003. Docetaxel was given at a dose of 75mg/m^2 by intravenous injection at dayl; Capecitabine was orally given at a dose of 2000mg/m^2/d, twice a day for two weeks followed by one week rest with 21 days apart for each cycle, at least two cycles weres given for the patient, Results： Among these 22 patients, the overall response rate was 68, 2% with 3 CR, 12 PR, 6 SD and 1 PD. The median TrP was 6.5 months. Grade Ⅰ-Ⅱ adverse effects were hyperpigmentation in 16（72.7%）, hand-foot syndrome in 14 （63.6%）, diarrhea in 10 （45.5%）, nausea and vomiting in 12 （54.5%） and leukopenia in 16 （72.7%）. Side-effect with grade Ⅲ-Ⅳ were anemia in 1 （4.5%）, leukopenia in 3（13.6%） and nausea and vomiting in 1 （4.5%）. Conclusions： Docetaxel combined with capecitabine is well tolerated and is an efficacious treatment for the patients with advanced breast cancer.
出处
《中国癌症杂志》
CAS
CSCD
2006年第3期229-231,共3页
China Oncology
